Skip to main content

Month: March 2024

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer and Doug Pace, Executive Vice President of Business Development will be attending the Future Food-Tech “Innovation & Investment from Farm to Fork” event March 21 – 22, 2024 at the San Francisco Marriott Marquis in California. Dyadic will be showcasing its Dapibus™ Microbial Expression System and providing updates on the...

Continue reading

LED Lighting and EV Charging Solutions Provider Orion to Webcast LD Micro Investor Conference Presentation Tuesday, April 9th at 9:00am ET

NEW YORK and MANITOWOC, Wis., March 21, 2024 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging station, and maintenance service solutions, announced it will be presenting at the 14th Annual LD Micro Invitational investor conference at the Sofitel New York Hotel, on Tuesday, April 9th at 9:00 a.m. ET. Orion’s management will also be available throughout the day for in-person investor meetings. Orion’s presentation is open to all investors via an online webcast available here. CEO Mike Jenkins and CFO Per Brodin will provide an overview of Orion’s business lines, value proposition, competitive position, cross-selling opportunities and growth outlook, followed by a Q&A session. Contact Dean Summers (dean@ldmicro.com) to register...

Continue reading

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.Event: H.C. Wainwright 2nd Annual Cell Therapy ConferencePresentation: March 26, 2024 at 2:00 p.m. ETFormat: Virtual fireside chat and one-on-one meetings   Event: Cantor Fitzgerald’s Muscular Dystrophy SymposiumPresentation: April 3, 2024 at 1:30 p.m. ETFormat: Virtual fireside chat   Dr. Linda Marbán, Capricor’s chief executive officer will present updates on Capricor’s recent progress on its lead program of CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD) as well as other general...

Continue reading

Cellebrite Files its 2023 Annual Report on Form 20-F

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 21, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a leader in premier Digital Investigative solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the “SEC”). Cellebrite’s 2023 Annual Report on Form 20-F is available on the investor relations section of its website at https://investors.cellebrite.com/financial-information/sec-filings and on the SEC’s website at www.sec.gov. Shareholders may request a hard copy of the 2023 Annual Report on Form 20-F, free of charge, by contacting the Company at investors@cellebrite.com. About Cellebrite Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save...

Continue reading

USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

-Yield10 achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina -Omega-3 Camelina potentially represents a novel solution to the market need for omega-3 oils used in aquafeed for farmed fish and in human nutrition WOBURN, Mass., March 21, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s Camelina sativa (“Camelina”) varieties developed using genetic engineering (modified Camelina) to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States. The global markets for omega-3 fatty acids include aquafeed used for...

Continue reading

Willis Lease Finance Corporation Completes Delivery of 4th ATR 72-500 Aircraft under its ConstantThrust® Engine Maintenance Program

COCONUT CREEK, Fla., March 21, 2024 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) announces it has successfully delivered its fourth ATR 72-500 aircraft to Transportes Aéreos Guatemaltecos (TAG Airlines) (“TAG”) as part of its lease agreements with the airline for four ATR 72-500 aircraft. The aircraft were overhauled and refurbished and fitted with new Pratt & Whitney Canada PW127M engines. Under the lease agreements, the aircraft are included in WLFC’s ConstantThrust® program for PW127M engines. WLFC will oversee the maintenance and care for the engines and will provide replacement engines as applicable. “We are thrilled to support TAG, our first regional ConstantThrust® airline partner, with a fourth aircraft delivery,” said Austin C. Willis, Chief Executive Officer of WLFC. “We value the relationship...

Continue reading

Intuitive Machines Reports Fourth Quarter and Full Year 2023 Financial Results

Delivered NASA and commercial payloads to the moon further south than any vehicle in history, marking the United States’ first lunar landing in over 50 years, on February 22, 2024 Supported by the FY 2024 NASA budget passed on March 8, 2024, Intuitive Machines contracts for CLPS and OMES III, as well as key future Artemis campaign contracts NSNS and LTVS were fully funded Validated the performance of the Company’s proprietary liquid methane and liquid oxygen propulsion system through the first-ever deep space ignition, resulting in a 7-day mission from launch to the lunar surface in Q1 Earned mission completion milestone payments from NASA and commercial customers of approximately $12.5 million following more than 144 hours of lunar surface operations Concluded 2023 with $268.6 million in backlog which nearly doubled in Q4 driven by...

Continue reading

Nano Dimension Announces Record 2023 Revenue of $56.3 Million and Organic Growth of 29%

Gross Margin Grew 41%; 45% vs. 32% Year-Over-Year Q4/2023 Revenue Grew 19% vs. Q4/2022 Conference Call to be Held Today at 9:00 AM EDT WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”), today announced financial results for the fourth quarter and full year ended December 31st, 2023. RevenueQ4/2023: $14.5 million, up 19% compared to Q4/ 2022 FY 2023: $56.3 million, up 29% compared to FY 2022Gross Margin (“GM”)FY 2023: 45%; up 41% from 32% in FY 2022Adjusted1 Gross Margin (“Adjusted GM”)FY 2023: 48%; vs. 46% in FY 2022Net Cash Burn² down 42% from 2022 to 2023:FY 2022: $146 million FY 2023: $84 million FY...

Continue reading

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Achieved Record Annual Revenues and EBITDA MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2023 Highlights Financial resultsRevenues were $328,199, an increase of $34,636 or 12% over prior year. Revenues excluding IAS 29 were $343,138, an increase of $51,368 or 18% over prior year. Gross margin was $152,652 or 47% compared to $138,061 or 47% in prior year. Adjusted EBITDA1 was $60,075, an increase of $6,043 or 11% over prior year. Adjusted EBITDA per share1 was $0.59, an...

Continue reading

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Figure 1Dose escalation and subject numbers by dose since initiating the trial in March 2023PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 37 patients in 6 cohorts since initiating the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.